Literature DB >> 11104571

Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.

G B Ragnarsson1, E K Mikaelsdottir, H Vidarsson, J G Jónasson, K Olafsdóttir, K Kristjánsdóttir, J Kjartansson, H M Ogmundsdóttir, T Rafnar.   

Abstract

Fas ligand (FasL) is expressed on some cancers and may play a role in the immune evasion of the tumour. We used immuno-histochemistry to study the expression of Fas and FasL in tissue samples from breast cancer patients, as well as normal breast tissue. Our results show that Fas and FasL are co-expressed both in normal tissue and in breast tumours. Fas and FasL mRNA were expressed in fresh normal and malignant breast tissue, as well as cultured breast epithelium and breast cancer cell lines. Flow cytometry analysis of live cells failed to detect FasL on the surface of normal or malignant breast cells; however, both stained positive for FasL after permeabilization. Fas was detected on the surface of normal breast cells and T47D and MCF-10A cell lines but only intracellularly in other breast cell lines tested. Neither normal breast epithelium nor breast cell lines induced Fas-dependent apoptosis in Jurkat cells. Finally, 20 tumour samples were stained for apoptosis. Few apoptotic cells were detected and there was no increase in apoptotic cells on the borders between tumour cells and lymphocytes. We conclude that FasL is expressed intracellularly in both normal and malignant breast epithelium and unlikely to be important for the immune evasion of breast tumours. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104571      PMCID: PMC2363445          DOI: 10.1054/bjoc.2000.1506

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 2.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

3.  Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies.

Authors:  D Smith; S Sieg; D Kaplan
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

Review 4.  Apoptosis by death factor.

Authors:  S Nagata
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.

Authors:  S Baskar; V K Clements; L H Glimcher; N Nabavi; S Ostrand-Rosenberg
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

6.  Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues.

Authors:  L Xerri; E Devilard; J Hassoun; C Mawas; F Birg
Journal:  Mol Pathol       Date:  1997-04

Review 7.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

8.  Human lung carcinomas express Fas ligand.

Authors:  G A Niehans; T Brunner; S P Frizelle; J C Liston; C T Salerno; D J Knapp; D R Green; R A Kratzke
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

9.  Apoptosis of crypt epithelial cells in ulcerative colitis.

Authors:  M Iwamoto; T Koji; K Makiyama; N Kobayashi; P K Nakane
Journal:  J Pathol       Date:  1996-10       Impact factor: 7.996

10.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

View more
  3 in total

1.  Countering the 'counterattack' hypothesis.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  Prognostic value of the Fas/Fas ligand system in breast cancer.

Authors:  Marek Bębenek; Danuta Duś; Joanna Koźlak
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

3.  Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.

Authors:  Toralf Reimer; Dirk Koczan; Heiner Müller; Klaus Friese; Hans-Jürgen Thiesen; Bernd Gerber
Journal:  Breast Cancer Res       Date:  2002-06-21       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.